Skip to main content

Advertisement

SpringerLink
Log in

Gastric acid hypersecretory states: Recent insights and advances

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Gastric acid hypersecretory states are characterized by basal hypersecretion of gastric acid and historically include disorders associated with hypergastrinemia, hyperhistaminemia, and those of unknown etiology. Although gastric acid secretion is infrequently measured, it is important to recognize the role of gastric hypersecretion in the symptoms of these disorders because they share several features of pathogenesis and treatment. In this article, recent important articles reporting insights into their diagnosis, pathogenesis, and treatment are reviewed. Particular attention is paid to Zollinger-Ellison syndrome, because it has the most extreme acid hypersecretion of this group of disorders and because numerous recent articles deal with various aspects of the diagnosis, molecular pathogenesis, and treatment of the gastrinoma itself or the acid hypersecretion. Two new hypersecretory disorders are reviewed: rebound acid hypersecretion after the use of proton pump inhibitors and acid hypersecretion with cysteamine treatment in children with cystinosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Schubert ML, Peura DA: Control of gastric acid secretion in health and disease. Gastroenterology 2008, 134:1842–1860.

    Article  CAS  PubMed  Google Scholar 

  2. Roy P, Venzon DJ, Feigenbaum KM, et al.: Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis: a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001, 80:189–222.

    Article  CAS  Google Scholar 

  3. Jensen RT, Gardner JD: Gastrinoma. In The Pancreas: Biology, Pathobiology and Disease, edn 2. Edited by Go VLW, DiMagno EP, Gardner JD, et al. New York: Raven Press; 1993:931–978.

    Google Scholar 

  4. Roy P, Venzon DJ, Shojamanesh H, et al.: Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000, 79:379–411.

    Article  CAS  Google Scholar 

  5. Nieto JM, Pisegna JR: The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006, 7:169–175.

    Article  CAS  PubMed  Google Scholar 

  6. Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469–1492.

    Article  CAS  PubMed  Google Scholar 

  7. Ellison EC, Johnson JA: The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009, 46:13–106.

    Article  PubMed  Google Scholar 

  8. Jensen RT: Gastrointestinal abnormalities and involvement in systemic mastocytosis. Oncol Hematol Clin North Am 2000, 14:579–623.

    Article  CAS  Google Scholar 

  9. Jensen RT: Treatment of pancreatic Zollinger-Ellison syndrome and other gastric hypersecretory states. In Therapy of Digestive Disorders. A companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases, edn 21. Edited by Wolfe MM. Philadelphia: WB Saunders; 2000:169–187.

    Google Scholar 

  10. Berna MJ, Hoffmann KM, Serrano J, et al.: Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006, 85:295–330.

    Article  CAS  Google Scholar 

  11. Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004, 83:43–83.

    Article  Google Scholar 

  12. Jensen RT, Berna MJ, Bingham MD, Norton JA: Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008, 113(7 Suppl):1807–1843.

    Article  PubMed  Google Scholar 

  13. Arnold R: Diagnosis and differential diagnosis of hypergastrinemia. Wien Klin Wochenschr 2007, 119:564–569.

    Article  CAS  PubMed  Google Scholar 

  14. Corleto VD, Annibale B, Gibril F, et al.: Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001, 15:1555–1561.

    Article  CAS  PubMed  Google Scholar 

  15. Murugesan SV, Varro A, Pritchard DM: Review article: strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009, 29:1055–1068.

    Article  CAS  PubMed  Google Scholar 

  16. Berna MJ, Hoffmann KM, Long SH, et al.: Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006, 85:331–364.

    Article  CAS  Google Scholar 

  17. Banasch M, Schmitz F: Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 2007, 119:573–578.

    Article  CAS  PubMed  Google Scholar 

  18. Jensen RT: Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006, 98:4–19.

    Article  CAS  PubMed  Google Scholar 

  19. Hirschowitz BI, Simmons J, Mohnen J: Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001, 15:1795–1806.

    Article  CAS  PubMed  Google Scholar 

  20. Dhillo WS, Jayasena CN, Lewis CJ, et al.: Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem 2006, 43:153–155.

    Article  CAS  PubMed  Google Scholar 

  21. Agreus L, Storskrubb T, Aro P, et al.: Clinical use of protonpump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009, 44:564–570.

    Article  CAS  PubMed  Google Scholar 

  22. Oh DS, Wang HS, Ohning GV, Pisegna JR: Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2006, 4:1467–1473.

    Article  PubMed  Google Scholar 

  23. Long SH, Berna MJ, Thill M, et al.: Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 2007, 92:4394–4402.

    Article  CAS  PubMed  Google Scholar 

  24. Goldman JA, Blanton WP, Hay DW, Wolfe MM: False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009, 7:600–602.

    Article  PubMed  Google Scholar 

  25. Shibata C, Funayama Y, Fukushima K, et al.: The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008, 12:344–349.

    Article  PubMed  Google Scholar 

  26. Norton JA, Alexander HA, Fraker DL, et al.: Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: a prospective study. Ann Surg 2003, 237:650–659.

    Article  PubMed  Google Scholar 

  27. Ishikawa Y, Yoshida H, Mamada Y, et al.: Curative resection of primary hepatic gastrinoma. Hepatogastroenterology 2008, 55:2224–2227.

    PubMed  Google Scholar 

  28. Weber HC, Venzon DJ, Lin JT, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995, 108:1637–1649.

    Article  CAS  PubMed  Google Scholar 

  29. Norton JA, Alexander HR, Fraker DL, et al.: Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004, 239:617–626.

    Article  PubMed  Google Scholar 

  30. Yu F, Venzon DJ, Serrano J, et al.: Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999, 17:615–630.

    CAS  PubMed  Google Scholar 

  31. Gibril F, Venzon DJ, Ojeaburu JV, et al.: Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001, 86:5282–5293.

    Article  CAS  PubMed  Google Scholar 

  32. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z: Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004, 89:1934–1938.

    Article  CAS  PubMed  Google Scholar 

  33. Perren A, Anlauf M, Henopp T, et al.: Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007, 92:1118–1128.

    Article  CAS  PubMed  Google Scholar 

  34. Anlauf M, Perren A, Kloppel G: Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 2007, 74:279–284.

    Article  PubMed  Google Scholar 

  35. Capelli P, Martignoni G, Pedica F, et al.: Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med 2009, 133:350–364.

    PubMed  Google Scholar 

  36. Berna MJ, Annibale B, Marignani M, et al.: A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multple endocrine neoplaisa type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008, 93:1582–1591.

    Article  CAS  PubMed  Google Scholar 

  37. Norton JA, Venzon DJ, Berna MJ, et al.: Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): long-term outcome of a more virulent form of HPT. Ann Surgery 2008, 247:501–510.

    Article  Google Scholar 

  38. Norton JA, Jensen RT: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004, 240:757–773.

    Article  PubMed  Google Scholar 

  39. Hoffmann KM, Gibril F, Entsuah LK, et al.: Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett’s esophagus. J Clin Endocrinol Metab 2006, 91:204–212.

    Article  CAS  PubMed  Google Scholar 

  40. Gibril F, Jensen RT: Diagnostic uses of radiolabeled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004, 36:S106–S120.

    Article  CAS  PubMed  Google Scholar 

  41. Berna MJ, Jensen RT: Uses of radiolabeled somatostatin receptor analogues in diagnosis of gastrointestinal neuroendocrine tumors. In A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Edited by Modlin IM, Oberg K. Hanover: Felsenstein CCCP; 2007:328–339.

    Google Scholar 

  42. Niederkohr RD, McDougall IR: Incidental gallbladder visualization on nonhepatobiliary nuclear medicine studies: case series and review of the literature. Clin Nucl Med 2007, 32:915–919.

    Article  PubMed  Google Scholar 

  43. Bunning J, Merchant SH, Crooks LA, Hartshorne MF: Indium-111 pentetreotide uptake by pancreatic polypeptide cell hyperplasia: potential pitfall in somatostatin receptor scintigraphy. Pancreas 2007, 35:372–375.

    Article  PubMed  Google Scholar 

  44. Kann PH: The value of endoscopic ultrasound in localizing gastrinoma. Wien Klin Wochenschr 2007, 119:585–587.

    Article  PubMed  Google Scholar 

  45. Sundin A, Garske U, Orlefors H: Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007, 21:69–85.

    Article  CAS  PubMed  Google Scholar 

  46. Gabriel M, Decristoforo C, Kendler D, et al.: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48:508–518.

    Article  CAS  PubMed  Google Scholar 

  47. Franz RC, Penzhorn HO: Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome? S Afr J Surg 2007, 45:58–60.

    CAS  PubMed  Google Scholar 

  48. Morocutti A, Merrouche M, Bjaaland T, et al.: An openlabel study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther 2006, 24:1439–1444.

    Article  CAS  PubMed  Google Scholar 

  49. Metz DC, Comer GM, Soffer E, et al.: Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006, 23:437–444.

    Article  CAS  PubMed  Google Scholar 

  50. Metz DC, Sostek MB, Ruszniewski P, et al.: Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007, 102:2648–2654.

    Article  CAS  PubMed  Google Scholar 

  51. Termanini B, Gibril F, Sutliff VE, III, et al.: Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998, 104:422–430.

    Article  CAS  PubMed  Google Scholar 

  52. Hirschowitz BI, Worthington J, Mohnen J: Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008, 27:1110–1121.

    Article  CAS  PubMed  Google Scholar 

  53. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.

    Article  CAS  PubMed  Google Scholar 

  54. Lorenz K, Dralle H: Surgical treatment of sporadic gastrinoma. Wien Klin Wochenschr 2007, 119:597–601.

    Article  PubMed  Google Scholar 

  55. Norton JA, Jensen RT: Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 2007, 205:S34–S37.

    Article  PubMed  Google Scholar 

  56. Norton JA, Fraker DL, Alexander HR, et al.: Surgery increases survival in patients with gastrinoma. Ann Surg 2006, 244:410–419.

    PubMed  Google Scholar 

  57. Plockinger U, Wiedenmann B: Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005, 19:553–576.

    Article  CAS  PubMed  Google Scholar 

  58. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005, 23:2754–2762.

    Article  CAS  PubMed  Google Scholar 

  59. Yao JC: Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007, 21:163–172.

    Article  CAS  PubMed  Google Scholar 

  60. Kulke MH, Lenz HJ, Meropol NJ, et al.: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403–3410.

    Article  CAS  PubMed  Google Scholar 

  61. Yao JC, Phan AT, Chang DZ, et al.: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26:4311–4318.

    Article  PubMed  Google Scholar 

  62. Patnaik MM, Rindos M, Kouides PA, et al.: Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007, 131:784–791.

    PubMed  Google Scholar 

  63. Blonski WC, Katzka DA, Lichtenstein GR, Metz DC: Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn’s disease. Eur J Gastroenterol Hepatol 2005, 17:441–444.

    Article  PubMed  Google Scholar 

  64. Desai AA, McGuigan JE, Draganov P: Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. Int J Gastrointest Cancer 2005, 35:157–161.

    Article  PubMed  Google Scholar 

  65. Qvigstad G, Waldum H: Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol 2004, 94:202–208.

    CAS  PubMed  Google Scholar 

  66. Hunfeld NG, Geus WP, Kuipers EJ: Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007, 25:39–46.

    CAS  PubMed  Google Scholar 

  67. Dohil R, Fidler M, Barshop B, et al.: Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005, 20:1786–1793.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, Bethesda, MD, 20892, USA

    Robert T. Jensen

Authors
  1. Nauramy Osefo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuhide Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert T. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert T. Jensen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osefo, N., Ito, T. & Jensen, R.T. Gastric acid hypersecretory states: Recent insights and advances. Curr Gastroenterol Rep 11, 433–441 (2009). https://doi.org/10.1007/s11894-009-0067-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-009-0067-6

Keywords

Search

Navigation